This trial is evaluating whether Trastuzumab deruxtecan will improve 2 primary outcomes and 10 secondary outcomes in patients with GEJ Adenocarcinoma. Measurement will happen over the course of Up to 16 months (data cut-off).
This trial requires 79 total participants across 1 different treatment group
This trial involves a single treatment. Trastuzumab Deruxtecan is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"The cure rate (100%) is very high (10%) for adenocarcinoma patients having a single liver metastasis. When the cancer is in a non-papillary area it achieves better results, however, the response rate (63%) is still very low." - Anonymous Online Contributor
"About 50% of adenocarcinoma cases are non-small cell cancers. Lung adenocarcinoma remains one of the most difficult tumors to cure due to the limitations of current therapies and the fact that some common treatment options such as surgery and radiotherapy have not shown promising results. There are also some cases of adenocarcinoma which are diagnosed via histology or cytopathology. These cases in which the tumor is removed from the body with minimal damage to other tissues have shown to be effective treatments in some cases." - Anonymous Online Contributor
"Signs of an adenocarcinoma may include loss of appetite, diarrhea, and weight loss. The liver may have enlarged (port-wine) or swollen (jugular) nodes, a rough surface texture, and a tender, pulsatile or a dull, aching consistency. The skin may be tender to the touch, with small patches of blue-gray macules with indistinct borders on the elbows, knees, ankles, or hands. The surface of the lips may be dry and chapped, numb, and blue-gray or blue. Other signs may include a bad bowel habit, and a vague feeling of uneasiness." - Anonymous Online Contributor
"Adenocarcinoma is a type of cancer that most commonly occurs in the large intestine (Colon) or in the stomach. The occurrence of small bowel carcinoma is relatively rare. It is a cancer that begins in a part of the large intestine (Colon) or the stomach. Adenocarcinoma commonly begins as adenoma and may also begin as a small polyp. It contains cancer in one or more of the large intestine (Colon), small bowel (i.e. duodenum and jejunum) or stomach. Adenocarcinoma begins in a part of the large intestine (Colon) and then continues to the stomach." - Anonymous Online Contributor
"The prevalence and incidence of adenocarcinoma of the oral cavity, pharynx, and larynx have increased in the US, while the incidence of adenocarcinoma of the esophagus, pancreas, liver, and colon have decreased or remained stable." - Anonymous Online Contributor
"Alcohol and tobacco smoking are both significant risk factors for adenocarcinoma of the rectum and colon. They also increase the risk of colorectal adenoma by 20-fold. They constitute one of the most common causes of colorectal adenocarcinoma and are important in the evaluation of patients with this problem." - Anonymous Online Contributor
"Based on our analysis of Medicare population-based data, the 5-year survival rate for stage T3 and N1 adenocarcinoma is about 50%. Data from a recent study shows that 5 year survival for stage T1N1, T2N0 (T1N0, T2N2, T3N0) is approximately 85% with no difference between ER/PR+ and ER/PR-. 5 year survival for T1N1 is more than 80% for ER/PR+, but less than 70% for ER/PR-." - Anonymous Online Contributor
"The safety and efficacy of trastuzumab deruxtecan in HER2-negative breast cancer was demonstrated. The safety and efficacy of trastuzumab deruxtecan for HER2-positive breast cancer were also established." - Anonymous Online Contributor
"Data from a recent study suggests that primary care should be considered in patients with adenocarcinoma and that it may be necessary to consider the possibility of adenocarcinoma in addition to colon or rectosigmoid adenocarcinomas in patients presenting with a long-standing history of colitis." - Anonymous Online Contributor
"Although there seems to be little need for routine CT of the abdomen, the data suggests that most patients had more advanced cancer than suspected on clinical suspicion alone. The most likely explanation is inadequate staging on clinical suspicion alone. CT is of no benefit as a screening test. A more comprehensive imaging investigation is recommended to address the possible discrepancy between clinical suspicion and imaging findings in patients with adenocarcinoma." - Anonymous Online Contributor
"In general, women who are >or= 50 years of age are more likely to have adenocarcinoma. Women who smoke cigarettes and have a family history of cancer are also at increased risk. Other factors seem unrelated to the development of adenocarcinoma. Because adenocarcinoma is much more frequent in the United States, the United States population needs further information about epidemiology of this type of cancer." - Anonymous Online Contributor
"Treatment with trastuzumab deruxtecan for an advanced breast cancer resulted in improvement in symptoms and tumor markers. However, only 13% of women responded to treatment and all progressed." - Anonymous Online Contributor